A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Public ClinicalTrials.gov record NCT06859424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Study identification
- NCT ID
- NCT06859424
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 358 participants
Conditions and interventions
Conditions
- AML (Acute Myelogenous Leukemia)
- Acute Lymphoid Leukemia (ALL)
- Acute Leukemia (Category)
- MDS (Myelodysplastic Syndrome)
- CML (Chronic Myelogenous Leukemia)
- CLL (Chronic Lymphocytic Leukemia)
- Prolymphocyctic Leukemia
- Chronic Myelomonocytic Leukemia (CMML)
- Myeloproliferative Neoplasm (MPN)
- Lymphoma
- Myelofibrosis
Interventions
- Conditioning Regimen A Drug
- Conditioning Regimen B Drug
- Conditioning Regimen C Drug
- Conditioning Regimen D Drug
- Conditioning Regimen E Drug
- Hematopoietic Cell Transplantation Procedure
- PTCy (50 mg/kg D3, D4) Drug
- PTCy (25 mg/kg D3, D4) Drug
- Post-transplant Tacrolimus Drug
- Post-transplant Mycophenolate mofetil Drug
- Post-transplant Abatacept Drug
- Post-transplant Ruxolitinib Drug
- Supportive Care: Growth Factors Drug
- Supportive Care: Blood Products Procedure
- Supportive Care: Infection Prophylaxis Other
- Supportive Care: Intravenous immune globulin (IVIG) Other
- Supportive Care: Seizure prophylaxis Drug
- Supportive Care: Monitoring and management of CRS Other
- Supportive Care: Prophylaxis against infections Other
- Supportive Care: Prophylaxis against infections Drug
- Supportive Care: Lipid elevations Other
- Study treatment compliance Other
- Prohibited Concomitant Therapy Other
- Permitted Concomitant Therapy Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years to 66 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 25, 2025 (Actual)
- Primary completion
- Jun 2028 (Estimated)
- Completion
- Jun 2028 (Estimated)
- Last update posted
- Mar 17, 2026
2025 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| City of Hope | Duarte | California | 91010 | Recruiting |
| Stanford | Palo Alto | California | 94304 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02446 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Memorial Sloan Kettering | New York | New York | 10065 | Recruiting |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | Recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Recruiting |
| University of Virginia | Charlottesville | Virginia | 22903 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06859424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06859424 live on ClinicalTrials.gov.